Fig 2: A, A comparison of the cerebrospinal fluid (CSF) concentrations of CXCL13 between CNS lymphomas and other CNS diseases (germ cell tumor, glioblastoma, other glioma, metastatic tumor, other brain tumor, multiple sclerosis, iNPH, and other diseases). The CSF CXCL13 levels of CNS lymphoma were significantly higher than those of the other diseases. (*P < .001). B, ROC curve of CSF CXCL13. AUC is 0.981. C, Immunohistochemistry of CXCL13 in CNS lymphoma specimens and other brain tumor specimens. The CXCL13 expression levels increased in the CNS lymphoma specimens compared with the other tumor specimens. (a-d) CNS lymphoma, (e-f) GBM, (g) anaplastic oligodendroglioma, (h) anaplastic astrocytoma, (i-j) diffuse astrocytoma, (k) ependymoma, and (l) medulloblastoma (original magnification: ×200). D, Immunohistochemistry of CXCR5 in the CNS lymphoma specimens (original magnification: ×200)

Fig 3: A, A comparison of the cerebrospinal fluid (CSF) concentrations of CXCL13, IL-10, sIL-2R, and ß2-MG in the prospective study. Patient data are shown in Table S2. The CSF levels of all biomarkers significantly increased in CNS lymphoma compared with the other diseases (*P < .001). B, ROC curve of CSF CXCL13, IL-10, sIL-2R, and ß2-MG in the prospective study. ROC is statistically significant (P < .001). AUC values are shown in each graph. C, Correlation of diagnosis by the 4-marker algorithm of CXCL13, IL-10, sIL-2R, and ß2-MG with pathological diagnosis in the prospective study. Sensitivity, specificity, positive predictive value, and negative predictive value are shown in the panels. The ROC curve of these combinations in the prospective study is shown in the right panel. D, Correlation of diagnosis by the 2-marker algorithm of CXCL13 and IL-10 with pathological diagnosis in the prospective study. Sensitivity, specificity, positive predictive value, and negative predictive value are shown in the panels. The ROC curve of these combinations in the prospective study is shown in the right panel